[{"id":"255cb565-f80f-4c68-9621-5cff2388d8ef","acronym":"NX-5948-301","url":"https://clinicaltrials.gov/study/NCT05131022","created_at":"2022-07-08T17:55:02.950Z","updated_at":"2024-07-02T16:34:59.140Z","phase":"Phase 1","brief_title":"A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies","source_id_and_acronym":"NCT05131022 - NX-5948-301","lead_sponsor":"Nurix Therapeutics, Inc.","biomarkers":" BCL2 • BCL6","pipe":"","alterations":" ","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bexobrutideg (NX-5948)"],"overall_status":"Recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 04/13/2022","start_date":" 04/13/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-06-04"}]